ANDA 91406, held by Mylan Labs Ltd. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 91406 (Doxycycline), held by Mylan Labs Ltd, was first approved by FDA on Aug 21, 2012, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 21, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| DoxycyclineEQ 100MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 18, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 16, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 21, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters